Short-Chain Guide RNA for Site-Directed A-to-I RNA Editing

Nucleic Acid Ther. 2021 Feb;31(1):58-67. doi: 10.1089/nat.2020.0866. Epub 2020 Nov 10.

Abstract

Site-directed RNA editing is a promising genetic modification technology for therapeutic and pharmaceutical applications. We previously constructed adenosine deaminases acting on RNA (ADAR)-guiding RNAs (AD-gRNAs) that direct A-to-I RNA editing activity of native human ADAR2 into a programmable target site. In this study, we developed the short-chain AD-gRNA (shAD-gRNA) as a potential basic framework for practical RNA-editing oligonucleotides. Based on knowledge of previous AD-gRNA, shAD-gRNAs were designed to have the shortest possible sequence for the induction of editing activity. In vitro, compared to the original AD-gRNA, the shAD-gRNAs showed similar or superior editing induction activity, depending on the target RNA sequence, and had lower off-target editing activity around the target site, which is predicted to be a hotspot for off-target editing. Moreover, shAD-gRNAs achieved target RNA editing with both exogenous and endogenous human ADARs in cultured cells. Our results present shAD-gRNA as a short basic framework that would be applicable to further development for practical RNA-editing oligonucleotides.

Keywords: A-to-I RNA editing; guide RNA; nucleic acid medicine; site-directed RNA editing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / genetics*
  • Base Sequence / genetics
  • Humans
  • Molecular Targeted Therapy*
  • Nucleic Acid Conformation
  • Oligonucleotides, Antisense / genetics*
  • RNA Editing / genetics*
  • RNA, Guide, CRISPR-Cas Systems
  • RNA, Messenger
  • RNA-Binding Proteins / antagonists & inhibitors
  • RNA-Binding Proteins / genetics*

Substances

  • Oligonucleotides, Antisense
  • RNA, Messenger
  • RNA-Binding Proteins
  • ADARB1 protein, human
  • Adenosine Deaminase